Celiac Research Partnership Builds Takeda’s GI Interests
This article was originally published in PharmAsia News
Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.
You may also be interested in...
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.